Microbiotica’s Microbiome Medicines in Melanoma and Ulcerative Colitis Gain Regulatory Approvals in EU and UK for Phase 1b Studies
Company Secures Additional Financing to Advance Clinical Programmes in Immuno-Oncology and Inflammatory Bowel Disease Through to Data Readout
The August edition of our People Pathways newsletter is out now! Read the newsletter here.
You can read about:
✅ One Nucleus upcoming courses - don't forget, as a One Nucleus member, you can access discounts up to 30%;
✅ Our upcoming BLSA SIG webinar on the Green Business Impact Programme jointly delivered by Allia and PECT;
✅ EBD Academy courses - member savings available;
and more...
The MycoScope™ Mycoplasma PCR detection kit from AMSBIO uses polymerase chain reaction (PCR) technology to detect mycoplasma infections in less than 3 hours. Offering high-sensitivity detection, rapid results, and compatibility with existing PCR setups, this kit reduces the risk of contamination spread saving valuable time and resources.
The biopharma industry veteran, founder of Medivation, and serial entrepreneur joins T-Therapeutics to support the development of the biotechnology company’s pipeline of next-generation soluble TCR therapeutics targeting cancer and autoimmune indications.
Cancer Research Horizons, the innovation arm of Cancer Research UK, has appointed Carlos Garcia-Echeverria, Katharina Kreymborg and Karen Lackey as the first members of its Therapeutic Innovation board to steer its drug discovery strategy.
Therapeutic Innovation is Cancer Research Horizons’ drug discovery division. From target identification to candidate drug nomination, Therapeutic Innovation’s scientists collaborate with academic and industrial partners to progress promising ideas, de-risk assets and bring projects to their next value inflection point.
This article will explore two commonly used sequencing methods, NGS vs Sanger Sequencing sequencing methods, looking at how they work, their respective advantages and disadvantages, and their applications.
Read our latest blog here:
https://sourcebioscience.com/ngs-v-sanger-sequencing/
Cellomatics Biosciences, a Nottingham-based preclinical contract research organisation, continues to expand its global client base by adding two new members of staff to support its business development efforts.
The company has welcomed Dr Pier Giorgio Amendola and Dr Jyoti Mundra to assist the company with its expansion into both European and US markets.